Meeting
2014 Genitourinary Cancers Symposium
Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC).
Authors
Rana R. McKay
Dana-Farber Cancer Institute, Boston, MA
Rana R. McKay , Kathryn P. Gray , Julia H. Hayes , Glenn J. Bubley , Jonathan E. Rosenberg , Philip W. Kantoff , Mary-Ellen Taplin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00658697
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 54)
DOI
10.1200/jco.2014.32.4_suppl.54
Abstract #
54
Poster Bd #
D10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.
First Author: Zin Myint
Poster
2023 ASCO Annual Meeting
Prime-boost immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer.
First Author: Mark N. Stein
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532).
First Author: Bertrand F. Tombal
Poster
2020 Genitourinary Cancers Symposium
A randomized phase II study of apalutamide (APA), androgen deprivation therapy (ADT), or APA + ADT in patients (pts) with biochemically relapsed (BCR) prostate cancer (PC).
First Author: Rahul Raj Aggarwal